These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 26205180)

  • 1. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
    Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
    Thomas JSJ; Provenzano E; Hiller L; Dunn J; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham J; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Caldas C; Bartlett JM; Cameron DA; Hayward RL; Earl HM
    Mod Pathol; 2017 Aug; 30(8):1069-1077. PubMed ID: 28548129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
    Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
    Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
    Bossuyt V; Provenzano E; Symmans WF; Boughey JC; Coles C; Curigliano G; Dixon JM; Esserman LJ; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Viale G; Cameron D;
    Ann Oncol; 2015 Jul; 26(7):1280-91. PubMed ID: 26019189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
    Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
    Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
    Litton JK; Regan MM; Pusztai L; Rugo HS; Tolaney SM; Garrett-Mayer E; Amiri-Kordestani L; Basho RK; Best AF; Boileau JF; Denkert C; Foster JC; Harbeck N; Jacene HA; King TA; Mason G; O'Sullivan CC; Prowell TM; Richardson AL; Sepulveda KA; Smith ML; Tjoe JA; Turashvili G; Woodward WA; Butler LP; Schwartz EI; Korde LA
    J Clin Oncol; 2023 Sep; 41(27):4433-4442. PubMed ID: 37433103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
    Maran-Gonzalez A; Franchet C; Duprez-Paumier R; Antoine M; Barlier C; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Fleury C; Garbar C; Ghnassia JP; Haudebourg J; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin Y; Roger P; Russ E; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
    Ann Pathol; 2019 Dec; 39(6):383-398. PubMed ID: 31257035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens.
    Provenzano E; Brown JP; Pinder SE
    Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):80-92. PubMed ID: 23199579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy.
    Pinder SE; Provenzano E; Earl H; Ellis IO
    Histopathology; 2007 Mar; 50(4):409-17. PubMed ID: 17448015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
    Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
    Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
    Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
    Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.
    Mrkonjic M; Berman HK; Done SJ; Youngson B; Mulligan AM
    J Clin Pathol; 2019 Feb; 72(2):120-132. PubMed ID: 30670564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
    Bossuyt V
    Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Bossuyt V; Provenzano E; Symmans WF; Webster F; Allison KH; Dang C; Gobbi H; Kulka J; Lakhani SR; Moriya T; Quinn CM; Sapino A; Schnitt S; Sibbering DM; Slodkowska E; Yang W; Tan PH; Ellis I
    Histopathology; 2024 Jun; 84(7):1111-1129. PubMed ID: 38443320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
    Bossuyt V; Symmans WF
    Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
    Lanjewar S; Patil P; Fineberg S
    Mod Pathol; 2020 Jan; 33(1):91-98. PubMed ID: 31383962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
    Provenzano E
    Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.